Launch new products including Foresight Universal Plus, FirstGene, Precise Tumor, Precise Liquid, and Precise MRD
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 27 Feb 2024
- Due
- 31 Mar 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“new product launches we expect in the second half of 2024 or early 2025 including, Foresight Universal Plus, FirstGene, Precise Tumor (relaunch) and Liquid, and Precise MRD”
What we found
Evidence strength A What the grades mean
The company's filings confirm the commercial availability of the specified products by listing them as part of their active product portfolio and revenue-generating categories following the deadline.
-
A Myriad Genetics Inc. 10-Q filed 2026-05-06
“The Company primarily generates revenue by performing molecular diagnostic testing, primarily derived from the following categories of products: Cancer Care Continuum (MyRisk, BRACAnalysis CDx, MyChoice CDx, Prolaris, Precise Tumor, and Precise MRD), Prenatal Health (Foresight, Prequel, FirstGene an” ✓ confirmed on the page
Market reaction: the shares moved -16.6% against the S&P 500 over the three sessions around the disclosure (5 May 2026 to 8 May 2026). What this measures
Checked 2 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Launch
- Deliverable
- Foresight Universal Plus, FirstGene, Precise Tumor, Precise Liquid, and Precise MRD
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Not met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Myriad Genetics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-MYGN-003937 · Corrections policy